Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alkermes (ALKS) Research & Development (2016 - 2025)

Alkermes (ALKS) has disclosed Research & Development for 16 consecutive years, with $93.0 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 59.93% to $93.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $324.0 million through Dec 2025, up 32.05% year-over-year, with the annual reading at $324.0 million for FY2025, 32.05% up from the prior year.
  • Research & Development for Q4 2025 was $93.0 million at Alkermes, up from $81.7 million in the prior quarter.
  • The five-year high for Research & Development was $118.4 million in Q3 2021, with the low at -$17.2 million in Q4 2021.
  • Average Research & Development over 5 years is $70.2 million, with a median of $72.9 million recorded in 2023.
  • The sharpest move saw Research & Development plummeted 115.37% in 2021, then soared 546.62% in 2023.
  • Over 5 years, Research & Development stood at -$17.2 million in 2021, then grew by 3.91% to -$16.6 million in 2022, then skyrocketed by 546.62% to $73.9 million in 2023, then decreased by 21.32% to $58.2 million in 2024, then soared by 59.93% to $93.0 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $93.0 million, $81.7 million, and $77.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.